Company’s New Groundbreaking Preclinical Data in NSCLC Models Provides Further Validation for SIL204's Innovative Delivery ...

Revolution Medicines Inc. (NASDAQ:RVMD) is one of the most promising stocks according to Wall Street analysts. On June 23, ...

Verastem shows strong late-stage pipeline progress, financial discipline, and a diverse portfolio that support long-term ...

Recent developments in protein-protein interactions (PPI) give hope for patients with advanced or untreatable diseases.

Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with ...

Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene - a gene that can cause cancer - that may play an important role in colon cancer. Researchers also showed how this ...

Amgen has transitioned into a mature, cash-generating pharma-biotech hybrid. Click here to find out why AMGN stock is a Buy.

Daraxonrasib gains FDA breakthrough therapy status for treating metastatic pancreatic cancer with KRAS G12X mutations, ...

In combination with a KRAS inhibitor, HotSpot’s CBM signalosome inhibitor achieved complete suppression of downstream signalling in KRASG12X cell lines. HotSpot’s CBM signalosome inhibitor ...

An RNA interference (RNAi) molecule that selectively targets the KRAS G12V mutation could represent a key advance in the treatment of cancer associated with this oncogenic variant. Researchers at the ...

We are advancing VS-7375 in the U.S. to target KRAS G12D mutant advanced solid tumors in areas of significant unmet need, such as pancreatic, colorectal, and lung cancers.” About KRAS G12D ...